Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merck and other ETFs, options, and stocks.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
72,000
Employees72,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
72,000
Employees72,000

MRK Key Statistics

Market cap
332.33B
Market cap332.33B
Price-Earnings ratio
146.04
Price-Earnings ratio146.04
Dividend yield
2.29%
Dividend yield2.29%
Average volume
6.91M
Average volume6.91M
High today
$131.32
High today$131.32
Low today
$129.81
Low today$129.81
Open price
$130.69
Open price$130.69
Volume
7.36M
Volume7.36M
52 Week high
$133.10
52 Week high$133.10
52 Week low
$99.14
52 Week low$99.14

MRK News

Simply Wall St 24h
Insiders At Merck Sold US$12m In Stock, Alluding To Potential Weakness

The fact that multiple Merck & Co., Inc. (NYSE:MRK) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongs...

Insiders At Merck Sold US$12m In Stock, Alluding To Potential Weakness
Benzinga 2d
Check Out What Whales Are Doing With MRK - Merck & Co - Benzinga

Loading... Loading... Investors with a lot of money to spend have taken a bullish stance on Merck & Co MRK. And retail traders should know. We noticed this t...

Check Out What Whales Are Doing With MRK - Merck & Co - Benzinga
Yahoo Finance 2d
Merck Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance

Merck (MRK) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MRK broke through the 20-day mov...

Merck Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance

Analyst ratings

84%

of 25 ratings
Buy
84%
Hold
12%
Sell
4%

More MRK News

Yahoo Finance 2d
The Zacks Analyst Blog Highlights Broadcom, Merck, Airbnb, ONEOK and PG&E - Yahoo Finance

For Immediate Release Chicago, IL – May 16, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research ana...

The Zacks Analyst Blog Highlights Broadcom, Merck, Airbnb, ONEOK and PG&E - Yahoo Finance
Yahoo Finance 3d
Top Stock Reports for Broadcom, Merck & Airbnb - Yahoo Finance

Wednesday, May 15, 2024 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports...

Top Stock Reports for Broadcom, Merck & Airbnb - Yahoo Finance
Yahoo Finance 4d
Merck Ends Keytruda Combo Melanoma Study Due to Futility - Yahoo Finance

Merck MRK announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor, Keytruda plus vibos...

Merck Ends Keytruda Combo Melanoma Study Due to Futility - Yahoo Finance
Simply Wall St 4d
Merck Insiders Sold US$12m Of Shares Suggesting Hesitancy - Simply Wall St

Many Merck & Co., Inc. ( ) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When evaluating insider tran...

Merck Insiders Sold US$12m Of Shares Suggesting Hesitancy - Simply Wall St
Yahoo Finance 5d
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment - Yahoo Finance

Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment Monday, Merck & Co Inc (NYSE:MRK) announced the dis...

Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment - Yahoo Finance
Seeking Alpha 5d
Merck discontinues testing of experimental skin cancer combo therapy

Merck (NYSE:MRK) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial. KeyVibe-010, a randomized Phase 3 tri...

Merck discontinues testing of experimental skin cancer combo therapy
Yahoo Finance 5d
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and ... - Yahoo Finance

RAHWAY, N.J., May 13, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the...

Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and ... - Yahoo Finance
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.